A Single-arm, Open, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in the Treatment of Urinary and Male Genital Tumors
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Anti-PD-L1 antibody Dragonboat Biopharmaceutical (Primary)
- Indications Bladder cancer; Penile cancer; Renal cancer
- Focus Therapeutic Use
- Sponsors Dragonboat Biopharmaceutical
- 25 Jan 2021 New trial record